Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and ...

In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity ...
Seeking Alpha

Clene’s CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament ...

CNM-Au8 ® treatment demonstrated significantly reduced plasma neurofilament light chain (NfL) levels compared to placebo at 24 weeks (p=0.04) Clene (CLNN) plans to discuss the totality of the survival ...
Nasdaq

Dermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 Weeks

In the intent to treat analysis, Dermata saw statistically significant differences in IGA treatment success, inflammatory lesion count, and non-inflammatory lesion count at week 4 (earliest measured ...
Business Insider

Dermata’s XYNGARI trial hits statistically significant difference at 4 weeks

Dermata Therapeutics (DRMA) announced that additional analysis of topline data from its Phase 3 STAR-1 trial showed that XYNGARI had a statistically significant difference from placebo on three ...